ABSTRACT Pathogenic coronaviruses are a major threat to global public health. Here, using a recombinant reporter virus-based compound screening approach, we identified small-molecule inhibitors that potently block the replication of severe acute respiratory syndrome virus 2 (SARS-CoV-2). Among them, JIB-04 inhibited SARS-CoV-2 replication in Vero E6 cells with a 50% effective concentration of 695 nM, with a specificity index of greater than 1,000. JIB-04 showed in vitro antiviral activity in multiple cell types, including primary human bronchial epithelial cells, against several DNA and RNA viruses, including porcine coronavirus transmissible gastroenteritis virus. In an in vivo porcine model of coronavirus infection, administration of JIB-04 reduced virus infection and associated tissue pathology, which resulted in improved weight gain and survival. These results highlight the potential utility of JIB-04 as an antiviral agent against SARS-CoV-2 and other viral pathogens.
【저자키워드】 SARS-CoV-2, coronavirus, Antiviral agents, JIB-04, 【초록키워드】 viruses, Coronavirus infection, coronavirus, Antiviral, in vitro, antiviral activity, virus, Replication, specificity, survival, virus infection, Vero E6 cell, in vivo, inhibitor, utility, reporter, SARS-CoV-2 replication, administration, gastroenteritis, cell types, acute respiratory syndrome, global public health, bronchial epithelial cells, viral pathogens, 50% effective concentration, DNA and RNA, approach, highlight, tissue pathology, greater, inhibited, reduced, compound screening, 【제목키워드】 activity,